Opioid Induced Constipation Market Report and Forecast 2024-2032

The market size is anticipated to grow at a CAGR of 7.2% during the forecast period of 2024-2032, likely to be driven by increasing use of opioids, awareness and recognition, aging population, research and development, regulatory approvals.

Opioid Induced Constipation: Introduction

Opioid Induced Constipation (OIC) is one of the most common and debilitating side effects of opioid medications. Opioids, which are often prescribed for pain management, primarily work by binding to specific receptors in the brain to relieve pain. However, they also bind to opioid receptors in the gut, leading to a range of gastrointestinal side effects, with constipation being the most prevalent. While constipation may seem like a minor inconvenience, for those who experience it chronically due to opioid therapy, it can significantly impact their daily life and overall well-being. In some cases, OIC can lead to serious health complications, such as faecal impaction or bowel obstruction.

Treatment for OIC typically begins with lifestyle and dietary changes, including increasing fluid and fibre intake and engaging in regular physical activity. Over-the-counter treatments, like stool softeners and laxatives, are often the first line of pharmacological therapy. If these are ineffective, prescription drugs specifically designed to treat OIC may be considered. Some of these medications work by blocking the opioid effect on the gut without affecting its pain-relieving properties on the brain.

Key Trends in the Opioid Induced Constipation Market

• Rising Opioid Consumption: With the increasing global prevalence of chronic pain conditions and subsequent rising opioid prescriptions, there's an associated rise in cases of OIC. This directly impacts the demand for OIC treatments.
• Emergence of Targeted Therapies: There's been a shift from general laxatives to more targeted treatments specifically designed for OIC. Drugs such as naloxegol (Movantik), methylnaltrexone (Relistor), and lubiprostone (Amitiza) have received approval specifically for OIC treatment.
• Direct-to-Consumer Advertising: Some pharmaceutical companies have taken to direct consumer advertising for OIC medications, making patients more aware of available treatments and potentially driving demand.
• Patient Education and Awareness: There's a growing emphasis on educating patients about OIC when they are prescribed opioids. This proactive approach helps in early identification and management of OIC.

Opioid Induced Constipation Market Segmentations

The market can be categorised into disease type, drug class, route of administration, dosage form, distribution channel, end user, and region.

Market Breakup by Product

• Mu-opioid Receptor Antagonists
• Chloride Channel-2 Activators
• Others

Market Breakup by Prescription Type

• Over the Counter
• Prescription

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Opioid Induced Constipation Market Overview

The opioid induced constipation (OIC) market revolves around the treatments and solutions developed to address the constipation caused by the use of opioids. As opioids continue to be a mainstay in pain management, especially in chronic conditions, the side effect of constipation has necessitated a distinct segment within the pharmaceutical market. Regulatory bodies like the FDA have given approvals to drugs specifically designed for OIC, validating the need for and importance of this market segment. The market is likely to see the entry of new drugs and treatments, given the continuous R&D focus.

Additionally, the global emphasis on personalized medicine might lead to more targeted and efficient OIC solutions. The North American market, particularly the United States, has been a significant player due to the high opioid prescription rates. Europe and parts of the Asia Pacific region, given their aging populations and increasing healthcare infrastructure, are also crucial regions for the OIC market.

Key Players in the Hemodialysis Vascular Grafts Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

The major companies in opioid induced constipation market are as follows:

• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Fresenius Kabi AG
• Hikma Pharmaceuticals PLC
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Bristol Myers Squibb Company
• GSK Plc.
• Bayer AG
• Aurobindo Pharma
• S.L.A. Pharma AG
• Salix Pharmaceuticals
• Takeda Pharmaceutical Company Limited

The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.